Progress in cardiovascular diseases 2012-01-01

A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.

Mark V Sherrid, Milla Arabadjian

Index: Prog. Cardiovasc. Dis. 54(6) , 483-92, (2012)

Full Text: HTML

Abstract

Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.Copyright © 2012 Elsevier Inc. All rights reserved.

Related Compounds

Related Articles:

Effect of GDNF on depressive-like behavior, spatial learning and key genes of the brain dopamine system in genetically predisposed to behavioral disorders mouse strains.

2014-11-01

[Behav. Brain Res. 274 , 1-9, (2014)]

Selective blockade of N-methyl-D-aspartate channels in combination with dopamine receptor antagonism induces loss of the righting reflex in mice, but not immobility.

2015-01-01

[Psychopharmacol. Ser. 232(1) , 39-46, (2015)]

A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.

1987-02-01

[Angiology 38(2 Pt 2) , 174-83, (1987)]

[Hypoglycemia induced or facilitated by disopyramide].

1988-01-01

[Rev. Med. Interne 9(5) , 528-9, (1988)]

Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.

1999-04-01

[Angiology 50(4) , 331-5, (1999)]

More Articles...